Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
:NMRA
Top Page
Neumora Therapeutics, Inc.
(NASDAQ:NMRA)
39Underperform
Positive Factors
Market Position
Neumora is back in the pole position to be first to market with a KORA in MDD due to aticaprant's development being on hold.
Pipeline Progress
Optimism remains for NMRA's broader pipeline, with new candidates like the M4 PAM for schizophrenia expected to advance to clinical trials.
Strategic Adjustments
Neumora recently announced plans to amend its ongoing KOASTAL-2 and -3 studies, adding additional stringency to site and patient selection to attempt to maximize the probability of success for the studies.
Negative Factors
Drug Efficacy Concerns
The failure of the KOASTAL-1 trial raises concerns about the efficacy potential of NMRA's class of drugs.
Investor Confidence
The discontinuation of Johnson & Johnson's aticaprant might hurt investor confidence in the near-term.
Market Skepticism
Investor skepticism may increase towards the KORA mechanism of action and other neuropsychiatry drug candidates due to the recent news.
Neumora Therapeutics, Inc. (NMRA) vs. S&P 500 (SPY)
Market Cap
$183.04M
Dividend YieldN/A
Average Volume (3M)1.48M
Price to Earnings (P/E)―
Beta (1Y)2.04
Revenue GrowthN/A
EPS Growth-0.42%
CountryUS
Employees110
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.53
Shares Outstanding161,978,930
10 Day Avg. Volume1,378,369
30 Day Avg. Volume1,476,418
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.67Price Target Upside490.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Neumora Therapeutics, Inc. Business Overview & Revenue Model
Company DescriptionNeumora Therapeutics, Inc. (NMRA) is a biotechnology company focused on developing precision medicines for neuropsychiatric and neurodegenerative disorders. The company leverages data-driven insights and neuroscience expertise to address the underlying biological pathways of brain diseases. Neumora's pipeline includes multiple investigational therapies targeting various neurological conditions, with a commitment to improving patient outcomes through innovative drug development.
How the Company Makes MoneyNeumora Therapeutics, Inc. generates revenue through the development and commercialization of its precision medicines. The company focuses on advancing its pipeline of investigational therapies through various stages of clinical trials, aiming for regulatory approval and subsequent market entry. Revenue is primarily derived from the successful commercialization of approved drugs. Additionally, Neumora may engage in strategic partnerships and collaborations with other pharmaceutical companies, which can include licensing agreements, joint ventures, or co-development arrangements, providing additional revenue streams and resources to support its research and development activities.
Neumora Therapeutics, Inc. Financial Statement Overview
Summary
Neumora Therapeutics, Inc. faces significant financial challenges with no revenue and substantial ongoing losses. The company has a strong cash position, which is vital for sustaining operations, but negative equity and consistent cash outflows highlight financial instability. The reliance on financing inflows indicates a dependency on external capital, a common trait for biotech firms in development stages.Income Statement
Neumora Therapeutics, Inc. has consistently reported zero revenue over the past several years, indicating a lack of monetization. All profitability metrics are negative, reflecting the company's inability to generate income. The company has significant ongoing losses, with a worsening EBIT and Net Income, suggesting high operational costs and financial strain typical for early-stage biotechnology firms.10
Very Negative
Balance Sheet
The company maintains a strong cash position relative to its total assets, indicating good liquidity. However, continuing losses have resulted in negative equity in some years, posing a risk. The debt-to-equity ratio is not meaningful due to negative equity in prior periods, but low total debt suggests limited leverage. The equity position improved slightly, but overall financial health is weak.20
Very Negative
Cash Flow
Neumora Therapeutics, Inc. shows consistent negative free cash flow, reflecting cash burn typical of R&D-heavy biotechnology companies. The cash flow from financing activities has been positive, indicating reliance on external funding to support operations. The operating cash flow has been negative, consistent with the lack of revenue generation.15
Very Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | -668.00K | -2.70M | -1.55M | 0.00 | EBIT |
| -263.46M | -188.19M | -135.87M | -237.32M | -95.52M | EBITDA |
| -263.46M | -187.53M | -135.28M | -236.78M | -95.41M | Net Income Common Stockholders |
| -243.79M | -235.93M | -130.90M | -237.31M | -99.27M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 307.58M | 453.98M | 371.88M | 409.25M | 191.98M | Total Assets |
| 316.97M | 496.19M | 426.23M | 429.30M | 197.95M | Total Debt |
| 1.85M | 5.23M | 8.44M | 2.05M | 2.04M | Net Debt |
| -140.29M | -368.81M | -232.50M | -407.19M | -189.93M | Total Liabilities |
| 29.91M | 27.12M | 873.08M | 754.52M | 292.33M | Stockholders Equity |
| 287.06M | 469.08M | -446.85M | -325.22M | -94.38M |
| Cash Flow | Free Cash Flow | |||
| -182.94M | -163.40M | -115.41M | -76.24M | -28.06M | Operating Cash Flow |
| -182.94M | -163.28M | -114.90M | -75.42M | -26.76M | Investing Cash Flow |
| -70.56M | 64.39M | -168.01M | -817.00K | -11.24M | Financing Cash Flow |
| 21.60M | 231.94M | 115.74M | 293.51M | 230.10M |
Neumora Therapeutics, Inc. Technical Analysis
Negative
1.13
Price Trends
1.72
Negative
5.86
Negative
8.87
Negative
Market Momentum
-0.28
Negative
30.86
Neutral
12.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMRA, the sentiment is Negative. The current price of 1.13 is below the 20-day moving average (MA) of 1.38, below the 50-day MA of 1.72, and below the 200-day MA of 8.87, indicating a bearish trend. The MACD of -0.28 indicates Negative momentum. The RSI at 30.86 is Neutral, neither overbought nor oversold. The STOCH value of 12.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NMRA.
Neumora Therapeutics, Inc. Risk Analysis
Neumora Therapeutics, Inc. disclosed 78 risk factors in its most recent earnings report. Neumora Therapeutics, Inc. reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Neumora Therapeutics, Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $2.80B | 12.35 | 38.89% | ― | 31.85% | ― | |
68 Neutral | $11.16B | 34.01 | 14.16% | ― | 24.81% | 33.67% | |
64 Neutral | $129.22B | ― | -3.15% | ― | 11.64% | -114.72% | |
51 Neutral | $6.18B | ― | -231.63% | ― | 42.53% | -15.29% | |
49 Neutral | $6.94B | 0.66 | -52.58% | 2.47% | 22.65% | 0.94% | |
48 Neutral | $498.00M | ― | -63.37% | ― | -52.30% | 27.13% | |
39 Underperform | $183.04M | ― | -64.48% | ― | ― | -0.42% |
* Healthcare Sector Average
Performance Comparison
NMRA
Neumora Therapeutics, Inc.
1.20
-11.24
-90.35%
ACAD
ACADIA Pharmaceuticals
17.23
-0.61
-3.42%
NBIX
Neurocrine
115.60
-24.65
-17.58%
VRTX
Vertex Pharmaceuticals
511.74
95.71
23.01%
SAGE
SAGE Therapeutics
8.21
-10.48
-56.07%
AXSM
Axsome Therapeutics
129.17
51.82
66.99%
Neumora Therapeutics, Inc. Earnings Call Summary
Earnings Call Date: Mar 3, 2025 | % Change Since: -27.56% | Next Earnings Date: May 13, 2025
Earnings Call Sentiment Neutral
The earnings call reflects a company in transition, with strong financials and leadership changes poised to drive future growth. However, setbacks in the KOASTAL-1 study and the discontinuation of bipolar depression trials pose significant challenges. The overall sentiment is balanced between optimism for future potential and caution due to current setbacks.Highlights
Strong Financial Position
Neumora ended 2024 with $307.6 million in cash, cash equivalents, and marketable securities, expected to support operations into mid-2026.
Pipeline Progress
Neumora has an industry-leading pipeline with seven programs targeting novel mechanisms of action, including the advancement of NMRA-511 in a Phase 1b study for Alzheimer's agitation and plans to progress the M4 franchise by mid-2025.
New Leadership Roles
Paul Berns has taken over as CEO and Josh Pinto has been appointed President, reflecting a strategic leadership restructuring.
Lowlights
KOASTAL-1 Study Failure
Navacaprant did not demonstrate a statistically significant improvement in the KOASTAL-1 Phase 3 study for MDD, leading to a pause in recruitment for KOASTAL-2 and 3.
Discontinuation of Bipolar Depression Study
The Phase 2 clinical trial investigating navacaprant for bipolar depression was discontinued to focus resources on the KOASTAL program.
Clinical Hold on NMRA-266
NMRA-266 has been on clinical hold for nearly a year due to preclinical convulsions observed, with no recent updates provided.
Company Guidance
In the call, Neumora Therapeutics provided detailed guidance on their ongoing and future clinical programs, emphasizing their strategic focus on addressing brain diseases. They reported advancements in their pipeline, including seven programs targeting novel mechanisms. Notably, they are optimizing their Phase 3 KOASTAL-2 and KOASTAL-3 studies for navacaprant in major depressive disorder (MDD) after the KOASTAL-1 study did not meet its endpoints. They have tested navacaprant in nearly 600 patients and plan to report top-line data for KOASTAL-3 in Q1 2026 and KOASTAL-2 in Q2 2026. Additionally, they discontinued navacaprant's Phase 2 trial for bipolar depression to focus resources on MDD. Neumora is also advancing NMRA-511 in a Phase 1b study for Alzheimer's agitation, with data expected by year-end. Financially, they ended 2024 with $307.6 million in cash, projecting operations support into mid-2026. Total operating expenses for 2024 were $243.8 million, primarily driven by their Phase 3 programs and business growth investments.Neumora Therapeutics, Inc. Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Neumora Therapeutics Announces Leadership Changes and Strategy
Neutral
Feb 13, 2025
On February 13, 2025, Neumora Therapeutics announced leadership changes effective February 14, 2025, with Paul L. Berns transitioning to CEO and Chairman of the Board. Other key executives such as Joshua Pinto, Bill Aurora, and Michael Milligan have been assigned new roles. These changes are part of the company’s strategic efforts to enhance its position in the industry. Additionally, the Board approved an option repricing plan to incentivize key personnel, subject to stockholder approval, reflecting Neumora’s commitment to retaining talent while advancing its neuroscience initiatives.
Private Placements and FinancingBusiness Operations and Strategy
Neumora Therapeutics Highlights Progress at Healthcare Conference
Positive
Jan 13, 2025
Neumora Therapeutics, Inc. presented a corporate update at the J.P. Morgan Healthcare Conference, highlighting its efforts in neuroscience drug development. The company, backed by a strong financial position with $850 million raised since 2021, aims to capitalize on multiple clinical catalysts expected in 2025, targeting a significant patient population across various neuropsychiatric and neurodegenerative disorders.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.